StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

422 Study Matches

SPR001-205 A Phase 2 Study to Evaluate the Safety, Pharmacokinetics,;and Exploratory Pharmacodynamics of SPR001 (Tildacerfont) in Children: Aged 6 to 17 Years with Congenital Adrenal Hyperplasia

The goal of this study is to test the safety and effectiveness of tildacerfont in children with congenital adrenal hyperplasia (CAH). When a child is enrolled in the study, in addition to taking the study drug (tildacerfont), he or she will continue to take his or her standard glucocorticoid doses. A part of the study will be to test different doses of the study drug and to measure adrenal hormones at each visit. Children will be in the study for 18 weeks and will have to visit the study clinic 5 times.

Principal Investigator: Kyriakie Sarafoglou
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: SITE00001409
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 2 to 17 years
• childhood diagnosis of classic congenital adrenal hyperplasia (CAH) a genetic mutation in CYP21A2
• currently taking steroids to treat CAH and on a stable dose for 1 month or more
Exclusion Criteria:

• clinically significant unstable medical or mental health condition (study staff will review)
• females who are pregnant or nursing
• unable to swallow medications
Conditions: Rare Diseases, Children's Health
Keywords: CAH, Congenital Adrenal Hyperplasia
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

The purpose of this study is to determine whether active Vagal Nerve Stimulation (VNS) Therapy is better than no stimulation VNS Therapy in improving health outcomes for subjects with Treatment-Resistant Depression (TRD). All participants in this study will receive a VNS Therapy surgical implant, which works to reduce the symptoms of depression by sending mild electrical pulses to the vagus nerve in the neck. The vagus nerve is connected to areas of the brain associated with controlling the mood. Data will be collected on responses to study treatments, quality of life, productivity, and use of healthcare services.

Principal Investigator: Ziad Nahas
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00000818
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• current diagnosis of major depression for at least two years or at least 4 episodes of major depression
• have an inadequate improvement in symptoms with at least 4 antidepressant treatments
• on at least one antidepressant with a stable drug schedule for at least 4 weeks
• enrolled in Medicare or Medicare Advantage
Exclusion Criteria:

• Currently uses, or is expected to use during the study, short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy
• acute suicide risk or suicide attempt within 6 months
• history of other major mental health diagnosis (staff will review)
• treatment with another device or experimental drug
Conditions: Mental Health & Addiction
Keywords: Depression, Major depression

Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR System in patients with severe symptomatic mitral regurgitation – APOLLO Trial (APOLLO)

The purpose of this study is to determine if replacing the mitral valve without open-heart surgery is as safe and effective as standard mitral valve surgery in patients with similar medical conditions. This system allows a bioprosthetic mitral valve (investigational valve) to be implanted through a long, thin, flexible tube that is inserted through an incision in the side of the chest or through an incision made in the groin area and through a vein in the leg. Participation in the study is expected to last approximately 5 years from the day the valve is implanted.

Principal Investigator: Greg Helmer
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00017497
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of moderate or severe mitral value regurgitation with symptoms
• multidisciplinary heart team thinks patient is not able to have treatment an approved transcatheter repair or conventional mitral valve procedure
Exclusion Criteria:

• prior transcatheter mitral valve procedure with device currently implanted
• left ventricular ejection fraction <30%
Conditions: Heart & Vascular
Keywords: Clinics and Surgery Center (CSC), Intrepid, Mitral valve, Mitral Valve Replacement, TAVR

Udall P1A4

Through this research, the study staff hopes to better understand how DBS works and to define the optimal site in the brain for DBS treatment for Parkinson’s Disease. You will be asked to come for one study visit where you will perform some physical and mental tasks while on and temporarily off your medications and DBS treatment. Participation in this research study will take 7-8 hours.

Principal Investigator: Jerrold Vitek
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00019735
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 10 years old
• diagnosis or suspected diagnosis of Parkinson's disease, Essential Tremor, or Dystonia
• implanted Deep Brain Stimulator (DBS)
• have a 7T MRI
Exclusion Criteria:

• history of dementia
• women who are pregnant or breastfeeding
• other exclusion criteria (study staff will review)
Conditions: Brain & Nervous System
Keywords: DBS, Dystonia, Essential Tremor, ET, Movement Disorders, Parkinson's, Parkinson's Disease, PD
I'm interested
Share via email
See this study on ClinicalTrials.gov

HEALEY ALS Platform Trial

The HEALEY ALS Platform Trial is a research trial that tests the safety and effectiveness of multiple treatments in ALS. A regimen is a specific course of treatment, each with a different study drug. We are doing this research to find out if different treatments have an effect on Amyotrophic Lateral Sclerosis (ALS). We also want to find out if these treatments are safe to take without causing too many side effects.

Principal Investigator: David Walk
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00000881
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18 years or older
• diagnosed with sporadic or familial ALS
• weakness started no more than 36 months ago -able to to swallow pills and liquids
Exclusion Criteria:

• unstable medical or mental health condition
• limitations on prior or current use of certain medications (study staff will review)
• women who are pregnant or breast feeding
Conditions: Rare Diseases, Brain & Nervous System
Keywords: Clinics and Surgery Center (CSC), ALS, amyotrophic lateral sclerosis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Self-Weighing for Weight Management in Adolescents Seeking Obesity Treatment: A Randomized Pilot

This study will test whether adding in daily weighing (5-7 days per week) is helpful in weight loss. In adults, it has been found to be helpful to have individuals who are obese to be more successful with their weight loss efforts if they weigh themselves at home every day. We want to see if this could be helpful in children as well. This research will last for about 12 weeks (3 months).

Principal Investigator: Carolyn Bramante
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00012679
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• aged 12 to <18 years
• BMI at the 95th percentile or greater
• weight loss or maintenance determined as the treatment goal by PWMC provider
Exclusion Criteria:

• any unhealthy weight control behaviors
• participation in other PWMC study
• developmental delay
• diagnosis that might cause weight fluctuations in weight
• severe anxiety or depression
Conditions: Children's Health
Keywords: children's health, obesity, weight, weight management
I'm interested
Share via email
See this study on ClinicalTrials.gov

COMPARE: Expanding first-line options for depression and matching treatments to patients: hatha yoga vs. behavioral therapy

We are studying treatment options for people who have depression. One group will practice hatha yoga and the other will have behavioral therapy. All treatments are done virtually via telehealth (computer) with no in person clinic visits.

Principal Investigator: Sabine Schmid
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00001751
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Symptoms of depression
• Able to read English or Spanish
• Live in states of NC, MA, MN, or RI
Exclusion Criteria:

• Bone fracture or joint surgery in the past 6 months
• Unable to walk
• Severe heart failure or lung disease
• Engaged in yoga practice or psychotherapy more than once in the past 4 weeks
• Currently pregnant
• Active suicidal or manic symptoms
Conditions: Mental Health & Addiction
Keywords: alternative therapies, Depression, yoga
Visit study website
I'm interested
Share via email

Testing ACL Reconstruction Outcome PredicTions (TAROT)

The purpose of this study is to see how accurately orthopaedic surgeons predict outcomes for people who have an anterior cruciate ligament (ACL) reconstruction. Patients will be asked to complete post-surgery surveys about occurrence of side effects, return to activity, reoperation, and satisfaction with the surgery at 4 months, 2 years, and 5 years.

Principal Investigator: Richard Kyle Martin
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021757
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• patients undergoing primary ACLR (anterior cruciate ligament reconstruction) at the University of Minnesota, Tria and CentraCare.
Conditions: Bone, Joint & Muscle
Keywords: ACL, anterior cruciate ligament, anterior cruciate ligament reconstruction, Clinics and Surgery Center (CSC), ortho surgeon prediction
I'm interested
Share via email

Syn-Sleep Study

The purpose of the study is to evaluate the use of the Syn-One Test for identifying patients with idiopathic rapid eye movement sleep disorder (iRBD) that will progress to synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies, pure autonomic failure and multiple system atrophy. Your participation will last approximately 2 years.

Principal Investigator: Michael Howell
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020941
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18 to 65
• diagnosis of Rapid Eye Movement (RBD) sleep disorder
• have repeated episodes of sleep related vocalizations and/or complex motor behaviors
• documented by sleep study to occur during REM sleep
Exclusion Criteria:

• diagnosis of Parkinson's disease, dementia, multiple system atrophy or any other cause
• unable to have a skin biopsy because of poor wound healing, use of anticoagulants other than aspirin or Plavix, or severe vascular disease
Conditions: Rare Diseases
Keywords: RBD, REM, REM Sleep Behavior Disorder (iRBD), Sleep
I'm interested
Share via email
See this study on ClinicalTrials.gov

Psychology and Health

The goal of this study is to learn more about how people make health-related decisions. Participants will complete two remote visits over Zoom, and answer questions about their beliefs, experiences, and health decisions they have made. They will also complete online computerized tasks. Total participation time is 2-3 hours.

Principal Investigator: Michael Bronstein
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00020029
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18 to 70 years
• have access to the Internet
• speak fluent English
Exclusion Criteria:

• unable to speak English
Conditions: Community Health, Prevention & Wellness, Mental Health & Addiction
Keywords: decisions, health, immunization, psychology, vaccine
I'm interested
Share via email

Development of objective measures for multisensory effects on hearing

Paired sound and electrical stimulation can alter how the brain encodes sounds and the perception of sounds, as shown in emerging evidence from animal studies. The aim of this study is to develop measures for paired stimulation that can be used reliably. These measures assess the following aspects of hearing: basic hearing sensitivity and cochlear health, perception of loudness and pitch, and perception of speech and music/complex sounds. This will lead to a greater understanding in the hearing science community about how multisensory stimulation can alter activity in the auditory system and sound perception, which may lead to new techniques for improving hearing disorders.

Principal Investigator: Hubert Lim
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00022175
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• not users of hearing aids or implanted devices
• normal hearing or hearing-impaired, with or without tinnitus
Exclusion Criteria:

• users of hearing aids or implanted devices
Conditions: Ear, Nose & Throat
Keywords: auditory plasticity, Hearing loss, neuromodulation, tinnitus, transcutaneous electrical stimulation
I'm interested
Share via email

Project SHINE (Sleep Health INitiative for Equity): Culturally informing a sleep extension intervention for African American adults

The purpose of the study is to better understand the experiences of healthy lifestyle behaviors (i.e., sleep and physical activity), and receive feedback on a sleep intervention that aims to improve sleep among African American adults who do not get enough sleep. Sleep is vital to engaging in a healthy lifestyle, living longer, and feeling energized throughout the day. This research will compare a sleep intervention program (“Sleep Intervention Group”) to a healthy homes education program (“Control Group”) to see if there are changes in sleep and physical activity among those in the Sleep Intervention Group. We expect that participants will be in this research study for about 6 weeks.

Principal Investigator: Ivan Wu
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00017901
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• not meeting Physical Activity Guidelines
• age range: 21 to 65 years
• body mass index range: 25.0 to 40 kg/m2
• average self-reported habitual sleep duration of ≤6 hours
• self-identify as Black or African American
Exclusion Criteria:

• self-reported organ-related disorder (COPD, cardiac arrhythmia, gastro-esophageal disorder)
• pregnant or less than 4 months postpartum
• infant living in household less than 1 year old
Conditions: Prevention & Wellness
Keywords: obesity, Physical Inactivity, Sedentary Behavior, Sleep. Insufficient sleep
I'm interested
Share via email
See this study on ClinicalTrials.gov

Brain Mechanisms of Qigong for Neuropathic Pain Relief in Adults with Spinal Cord Injury

The researchers aim to prove that Qigong practice can result in reduced or relieved neuropathic pain, improved mood, life satisfaction, self-efficacy, enjoyment to move, and community integration; and decreased fear of movement, use of medication or health care services for adults with spinal cord injury.

Principal Investigator: Ann Van de Winckel
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00011997
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18 to 75 years old
• spinal cord injury (SCI) at least 3 months ago
• medically stable with paraplegia (T1 and below) or tetraplegia (C4 and below)
• highest level of below-level SCI-related neuropathic pain >3 on the numeric pain rating scale.
Exclusion Criteria:

• unable to have a MRI (stabilizing hardware is typically MRI safe)
• uncontrolled seizure disorder; cognitive impairment and/or communicative disability (e.g., due to brain injury) that prevent the participant from following directions or from learning
• ventilator dependent
• pregnant or plans to become pregnant during study
• inability to perform kinesthetic imagery
Conditions: Brain & Nervous System
Keywords: SCI, Spinal Cord Injury
I'm interested
Share via email
See this study on ClinicalTrials.gov

Humanitarian Use Device: Medtronic DBS Therapy for Dystonia (HDE #H020007) (Dystonia IRB)

Humanitarian use devices are medical devices approved by the FDA for the treatment of medical conditions affecting fewer than 4,000 patients per year. The FDA reviewed the safety of the device and determined that the probable health benefits outweigh the risks of injury or illness from its use. Effective treatment of symptoms, however, has not been studied in formal clinical trials. Medtronic DBS Therapy delivers electrical stimulation to areas in the brain to help control symptoms of various movement disorders. You may be a candidate for Medtronic DBS Therapy for Dystonia if you have been diagnosed with chronic, intractable (drug refractory) primary dystonia. You or your third party payer (health insurance, Medicare, Medicaid or other) must provide payment for hospital, office and other medical costs related to this therapy.

Principal Investigator: Jerrold Vitek
Age Group: 7 years and over
This study is NOT accepting healthy volunteers
IRB Number: 1207M17701
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 7 to 99 years old
• diagnosed with chronic, intractable (drug refractory) primary dystonia determined by a neurologist or neurosurgeon
Exclusion Criteria:

• patients who are at significant surgical risk as determined by the neurosurgeon and/or anesthesiologist
• patients who have not had an adequate trial of medical or non-surgical treatment
Conditions: Brain & Nervous System
Keywords: DBS, Deep Brain Stimulation, Dystonia
I'm interested
Share via email
See this study on ClinicalTrials.gov

Assessment of usability and satisfaction with a take-home device presenting sound and body stimulation for back pain

The purpose of this study is to measure the compliance, usability, and satisfaction of an at-home, multi-modal stimulation device in a diverse population of people with chronic lower back pain (cLBP) compared to a group of participants who are engaging in integrative health practices. The multi-modal device will include a combination of electrical stimulation, auditory stimulation, and integrative-health techniques, including mindfulness breathing, health coaching, and reflective journaling. The multi-modal device creation is based on prior knowledge in lower back pain treatment, which includes electrical stimulation of the back (Transcutaneous Electrical Nerve Stimulator or TENS) and integrative health modalities. Findings from this usability pilot study could help refine the approach and the multi-modal device for a future intervention study in cLBP participants.

Principal Investigator: Hubert Lim
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021883
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• must have chronic lower back pain, defined as back pain lasting 3 or more months,
• willing to travel to the University of Minnesota and commit to the study duration
Exclusion Criteria:

• cannot have any implanted stimulation devices
Conditions: Bone, Joint & Muscle
Keywords: Back Pain
I'm interested
Share via email

Visual Perception in Visual Snow Syndrome

This study seeks to understand visual perception in people with Visual Snow Syndrome and how this relates to brain function.

Principal Investigator: Michael-Paul Schallmo
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00014113
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Between 18 - 60 years old
• Good general physical health
• No history of other neurological disorders or problems
• Fluent in English
Conditions: Vision & Eyes
Keywords: Visual snow, visual snow syndrome
I'm interested
Share via email
See this study on ClinicalTrials.gov

Development of Tobacco Related Biomarkers

To maintain a biorepository (sample bank) of biological samples from different tobacco users and non-users to investigate how tobacco and nicotine products affect our bodies. The samples will be used by researchers to develop methods to look for biological “markers” (biomarkers), or chemical changes in the body, that occur due to tobacco or nicotine exposure. The goal is to eventually use these biomarkers to improve detection, prevention, and treatment strategies for tobacco-related diseases.

Principal Investigator: Stephen Hecht, PhD
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00021394
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
This study is recruiting people who fit one of the following:
• formerly smoked cigarettes daily
• uses smokeless tobacco
• smokes cigars
• uses nicotine gum, lozenges, patches, nasal spray, pouches, or inhaler
Exclusion Criteria:

• younger than 21 years old
• smokes or vapes marijuana
Conditions: Community Health, Prevention & Wellness
Keywords: chewing, cigarettes, cigars, nicotine, smokeless tobacco, smoking, tobacco, vaping, gum, patches
I'm interested
Share via email

Influence of Exercise on the Gut Microbiome of Overweight and Obese Adults with Prediabetes

We are looking at how an 8-week exercise program of walking for 30-45 minutes 3 times/week affects the body. This study is for people who are prediabetic and overweight or obese. We will compare the exercise group to a group that didn’t participate in the exercise to see if there are differences in gut microbes, body measurements, and blood work.

Principal Investigator: Ryan Demmer
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00009136
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 30-64 years old
• classified as overweight or obese with BMI greater than 25 kg/m2
• physician diagnosed as pre-diabetic or HbA1c value of 5.7 - 6.4% obtained during study screening
• currently exercise less than 100 minutes per week
• physically able to exercise
• no antibiotics taken for at least 45 days
• weight has been stable for the last 6 months (less than 10% change)
• willing to maintain current diet and exercise levels unless changed by the study
Exclusion Criteria:

• current gastrointestinal illness
• taking metformin or other medications for high blood sugar
• history of bariatric surgery
• pregnant or breast feeding
Conditions: Diabetes & Endocrine
Keywords: Prediabetes, elevated blood glucose, impaired glucose, blood sugar, obesity, Hemoglobin A1c, exercis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Sex differences in the effecTs of brEaking uP sedentary behavior on vascUlar function in Type 2 Diabetes (STEP UP T2D)

Type 2 diabetes (T2D) confers a high risk of cardiovascular disease (CVD), particularly among older adults who tend to be physically inactive. Most studies that have examined the effects of changing sedentary behavior (SB) have focused on young healthy males and prioritized glycemic outcomes. We will look at the effect of 3 different ways of breaking up sitting: 1) 4 hours of prolonged SB, 2) 4 hours of SB broken up by 5 minutes of self-paced walking every hour, and 3) 4 hours of SB with one 20-minute bout of self-paced walking. In addition to examining the overall effects of each condition, differences between men and women will be evaluated.

Principal Investigator: Mary Whipple
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00018030
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• men who are 60 years or older
• Type 2 diabetes (hemoglobin A1c 6.5% or more and/or previous diagnosis of type 2 diabetes)
• sedentary for at least 6 hours/day
• willing to abstain from food, caffeine, alcohol and exercise for at least 24 hours, and tobacco/smoking for at least 12 hours prior to each study visit
• able to speak and read English
Exclusion Criteria:

• Type 1 diabetes
• uncontrolled hypertension (resting systolic greater than 160 or diastolic greater than 110 mmHg)
• starting hormone therapy or changing in hormone therapy (dose/frequency/route of administration) in the previous 3 months
• on renal dialysis
• history of deep vein thrombosis (DVT)
• evidence of cognitive impairment
• physical impairment or disability that interferes with ability to engage in exercise (severe osteoarthritis, lower extremity amputation [other than toe(s)/partial foot], use of a walker or wheelchair, etc.)
• unstable medical/psychiatric condition that could impact study participation
Conditions: Diabetes & Endocrine, Prevention & Wellness, Women's Health
Keywords: physical activity, sedentary behavior, sitting
I'm interested
Share via email
See this study on ClinicalTrials.gov

teleABLE: Adapting a Behavioral Activation-Based Intervention to Reduce Post-Stroke Sedentary Behavior using Telehealth (Main Trial)

We are exploring ways to promote healthy lifestyles during stroke rehabilitation using a web-based rehabilitation program. The purpose of this study is to compare two intervention approaches: teleABLE and Healthy Lifestyles Education. Both interventions are delivered using video visits, so participants can complete all study activities from home

Principal Investigator: Emily Kringle
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021288
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years old
• diagnosed with stroke more than 6 months ago
• report 6 or more hours of sedentary behavior on a typical day
• live in a community-based setting (i.e., personal residence, assisted living facility)
• mobile within the home, with or without an assistive device and without physical assistance
Exclusion Criteria:

• Stroke participants will be excluded if:
• currently receiving chemotherapy or radiation treatments for cancer
• have a medical diagnosis of neurodegenerative disorder (i.e., dementia, Parkinsons disease, multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma)
• received inpatient treatment for substance use disorder or psychiatric condition within the past 12 months
• have a history of skin sensitivity related to adhesives
• pregnant or expecting to become pregnant in the next 2 months
• live in an institutional setting
• currently incarcerated
• stroke participants will also be excluded if they have severe aphasia
Conditions: Brain & Nervous System
Keywords: CVA, physical therapy, rehabilitation, remote, Stroke, virtual
Visit study website
I'm interested
Share via email

NAPS2: North American Prodromal Synucleinopathy Consortium Stage 2

We are recruiting only healthy participants who do not have REM sleep behavior disorder. The information gained from this study will help the investigators understand more about REM sleep behavior disorder (RBD), and the possible underlying neurologic disorders that can cause RBD.

Principal Investigator: Michael Howell
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: SITE00001442
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• male
• 54 to 75 years old
• Caucasian
Exclusion Criteria:

• history of dream enactment
• diagnosis of Parkinson's Disease, dementia, MCI, or MSA
• blood relative with REM Sleep Behavior Disorder
Conditions: Brain & Nervous System, Breathing, Lung & Sleep Health
Keywords: Clinics and Surgery Center (CSC), control, neurology, Parkinson's Disease, REM Sleep Behavior Disorder, sleep, RBD
Visit study website
I'm interested
Share via email

Mechanisms and effects of pallidal deep brain stimulation on levodopa resistant motor signs in Parkinson's disease; Udall Project 2, Aim 2

We hope to identify patterns in the brain that may be related to symptoms of PD, such as problems with walking. We are also testing different stimulation settings to see if they might be more effective than the settings that are currently used for treatment. This research may aid in our understanding of PD and how to treat it more effectively with DBS.

Principal Investigator: Colum MacKinnon
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00016988
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• receiving DBS therapy in for treatment of Parkinson's Disease (PD)
• implanted with Medtronic Percept DBS system
• at least 3 months since initial activation of the DBS
Exclusion Criteria:

• musculoskeletal disorders that significantly affect the ability to perform the motor tasks
• dementia or cognitive impairment
• other significant neurological disorders
• post-operative complications or adverse effects of the DBS stimulation
Conditions: Brain & Nervous System
Keywords: Clinics and Surgery Center (CSC), DBS, Deep Brain Stimulator, Parkinson Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinsons disease; Udall Project 2 Aims 1 & 2 Study

This protocol will characterize the effects of deep brain stimulation (DBS) location (both adverse and beneficial) on motor signs in people with Parkinson’s disease (PD). This information can be used to inform future DBS protocols to tailor stimulation to the specific needs of a patient. If targeted dorsal GP stimulation is shown to significantly improve motor features that are typically resistant to dopamine replacement therapy, these experiments will likely have major impact on clinical practice by providing a potential strategy to treat medically intractable symptoms.

Principal Investigator: Colum MacKinnon
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: 1608M93561
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of idiopathic Parkinson's Disease (PD)
• have a deep brain stimulator (DBS)
• have had a 7T brain scan
Exclusion Criteria:

• history of musculoskeletal disorders that significantly affect movement of the upper or lower limbs
• other significant neurological disorder
• history of dementia or cognitive impairment
• post-operative complications or adverse effects of DBS
Conditions: Brain & Nervous System
Keywords: Clinics and Surgery Center (CSC), DBS, Deep Brain Stimulator, Parkinson's Disease, PD
I'm interested
Share via email
See this study on ClinicalTrials.gov

Kinematic signatures of postural instability and gait in Parkinson Disease

The purpose of this research is to better understand balance and walking in patients with Parkinson’s Disease. This research study uses small wearable devices that attach to clothing and can measure the body’s location while performing walking and balance tests.

Principal Investigator: Robert McGovern, MD
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00005877
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• People diagnosed with Parkinson's disease, with or without implanted Deep Brain Stimulator (DBS). May be at any age of disease progression.
• Healthy adults of similar age to participants who have Parkinson's Disease and are enrolled in the study.
Exclusion Criteria:
People who have dementia of sufficient severity to impair their ability to make health-care decisions for themselvess
Conditions: Brain & Nervous System
Keywords: Parkinson's, Parkinson's Disease, Deep Brain Stimulator, DBS
I'm interested
Share via email

Causal Modeling of Ecological Momentary Assessment and Wearable Data in Youth

Researchers want to find out more about how physical, cognitive, and emotional factors affect eating.

Principal Investigator: Amy Gross
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021073
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 13-17 years old
• BMI at or above the 95th percentile
• own a smartphone
• willing to wear a FitBit or Garmin that we provide, download the FitBit or Garmin app on your smartphone and allow transfer of data to study staff
Exclusion Criteria:

• medication changes in the last 28 days for medications that are likely to affect appetite, mood, and attention
Conditions: Brain & Nervous System, Children's Health
Keywords: adolescents, Eating behaviors
I'm interested
Share via email

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

We are studying how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating people with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.

Principal Investigator: Edward Greeno, M.D.
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC045
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), with or without bevacizumab
• tumor determined to be mismatch-repair deficient (dMMR)
• able to walk & do selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• additional criteria apply (study staff will review)
Exclusion Criteria:

• women who are pregnant or breast feeding
• treatment with oxaliplatin chemotherapy within 6 months prior to randomization
• history of significant liver, heart, lung, or autoimmune disease etc. (study staff will review)
Conditions: Cancer
Keywords: Colon Cancer, Metastatic Colorectal Adenocarcinoma, Rectal Cancer, Stage IV Colorectal Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients

We are looking at the addition of nivolumab to chemotherapy compared to usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body. Immunotherapy, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells. Giving nivolumab with chemotherapy may help doctors find out if the treatment is better or the same as the usual approach.

Principal Investigator: Edward Greeno, M.D.
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC037
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• inoperable, recurrent, or metastatic anal cancer
• restricted from strenuous activity but can walk and are able to carry out work of a light or sedentary nature
• requirements for lab results at a defined level (study staff will review)
• history of significant heart disease
Exclusion Criteria:

• women who are pregnant or breastfeeding
• previous use of systemic chemotherapy or other investigational drugs
• prior immunotherapy
• active autoimmune disease or history of autoimmune disease
• other primary cancer within the last 3 years
• intermittent peripheral neuropathy
• additional exclusion criteria that study study will review
Conditions: Cancer
Keywords: Anal Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

We are studying how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Principal Investigator: Kiran Lassi
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC030
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of HER2-positive breast cancer
• received neoadjuvant (before surgery) chemotherapy
• had surgery that removed all disease in the breast and lymph nodes
• restricted from strenuous activity but can walk and do work of a light or sedentary nature, e.g., light house work, office work
• additional criteria apply (study staff will review)
Exclusion Criteria:

• women who are pregnant or breastfeeding
• history of prior invasive breast cancer within past 3 years
• peripheral neuropathy that is more than intermittent & mild
• see link to clinicaltrials.gov for additional exclusion criteria
Conditions: Cancer
Keywords: Breast Cancer, HER2 Positive Breast Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

The Women Kidney Program

The purpose of this study is to capture clinical information on how kidney disease affects the health of women, focusing on menstrual and reproductive health, the transition to menopause (the time when your menstrual periods stop permanently), and menopause itself. We also wish to learn more about how women’s health affects their kidney disease, bone and heart health.

Principal Investigator: Angie Lobo Romero
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020957
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• female as biological sex
• diagnosis of a kidney disease or after kidney transplant
• at least 18 years old
Exclusion Criteria:

• unable to speak English
Conditions: Kidney, Prostate & Urinary, Women's Health
Keywords: Clinics and Surgery Center (CSC), Kidney disease, kidney transplant
I'm interested
Share via email

Personalized Nutrition Therapy Using Continuous Glucose Monitoring to Improve Outcomes in Type 2 Diabetes Mellitus

The purpose of this research study is to learn more about how food affects blood sugar levels, and whether a continuous glucose monitor (CGM) can help to individualize nutrition education for people with diabetes. Participation in the study would require 3-4 clinic visits over a period of 14 weeks. Participants will also be asked to: meet with a registered dietitian every 2 weeks (virtually), keep food logs, wear a CGM and an activity monitor, answer survey questions, and provide blood samples to measure markers of diabetes control (like hemoglobin A1c).

Principal Investigator: Anne Bantle
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00019848
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years of age
• diagnosis of type 2 diabetes mellitus
• Hemoglobin A1c of 7.0 - 9.5%
• Stable medications for diabetes for at least 3 months prior to enrollment, with no plans to change medications or doses during the intervention period
Exclusion Criteria:

• Type 1 diabetes mellitus
• treatment with insulin, sulfonylurea, or meglitinide
• use of a nondiabetic medication affecting blood glucose (e.g. corticosteroid)
• BMI < 25 kg/m2
• weight change > 5 pounds in the 3 months prior to study enrollment
• estimated glomerular filtration rate <60 ml/minute/1.73 m2
• pregnant or breastfeeding
• anemia
• presence of any disease that would make adherence to the protocol difficult
Conditions: Diabetes & Endocrine
Keywords: Diabetes, T2D, Type 2 Diabetes
I'm interested
Share via email